AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04927338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
Trial: NCT05083260
Drug: NE3107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
Trial: NCT05083260
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsule containing only common excipients for oral formulations
Trial: NCT05150587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT06178757
Drug: EOIB
RxNorm normalized name: Ethinyl Estradiol and Norgestimate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
Trial: NCT05197075
Drug: DRV/COBI FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/COBI FDC tablet dispersed in water will be administered orally.
Trial: NCT04876651
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enzalutamide or abiraterone \[+ prednisone/prednisolone)\] or docetaxel
Trial: NCT05620017
Drug: BAT8008 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
Trial: NCT05098327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills containing cellulose 1 pill daily will be given for 12 weeks
Trial: NCT05431634
Drug: Experimental drug: ESK-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of ESK-001
Trial: NCT06271564
Drug: Magnetite ZnO Composite Nanoparticles
RxNorm normalized name: magnesite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
Trial: NCT06271564
Drug: Topical Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
Trial: NCT04768868
Drug: IMP7068
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
Trial: NCT05154240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05219968
Drug: LYR-210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYR-210 drug matrix (mometasone furoate)
Trial: NCT05219968
Drug: Sham procedure control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure control
Trial: NCT05738460
Drug: antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
Trial: NCT05582096
Drug: LY3457263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05582096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05923086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration before major meal
Trial: NCT06223841
Drug: IAP0971
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAP0971 should be subcutaneous injected，q3w
Trial: NCT05797883
Drug: FOLFOX/FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
Trial: NCT05706636
Drug: oral mini pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg / week oral dexamethasone
Trial: NCT05706636
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical fluticasone cream for body lesions and topical tacrolimus for face lesions
Trial: NCT04732247
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal treatment with placebo via nasal spray
Trial: NCT05490940
Drug: Tisseel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~1. Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~2. Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc).
Trial: NCT04031573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via the enteral route, every 12 hours.
Trial: NCT04661475
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
Trial: NCT05710198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops containing placebo matching product
Trial: NCT04703257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
Trial: NCT00002093
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05763082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04826497
Drug: Placebo（normal saline）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
Trial: NCT06177171
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Orally
Trial: NCT06031597
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
Trial: NCT06031597
Drug: Immunotherapeutic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
Trial: NCT05730972
Drug: Routine palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
Trial: NCT04996199
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
Trial: NCT04959500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
Trial: NCT00000636
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04583462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
Trial: NCT05598177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will pump saline without dexmedetomidine at the same speed as group D.
Trial: NCT06014736
Drug: XJ101 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
Trial: NCT06014736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains only excipients.
Trial: NCT06084676
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
Trial: NCT04826328
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single peripheral nerve injection
Trial: NCT06618105
Drug: Test Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo of T inhalation aerosol
Trial: NCT06618105
Drug: Reference Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo of R inhalation aerosol
Trial: NCT06625840
Drug: MK-1167
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT06625840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT05503693
Drug: AP303 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP303 tablet
Trial: NCT05503693
Drug: AP303 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP303 tablet
Trial: NCT05503693
Drug: AP303 600 μg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP303 tablet
Trial: NCT05503693
Drug: Placebo 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05503693
Drug: Placebo 600 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05350124
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vitamin C (200 mg) capsule
Trial: NCT05350124
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two pills only
Trial: NCT06019013
Drug: QLF3108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLF3108 will be administered independent of body weight.
Trial: NCT05241054
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 1 microgram.kg
Trial: NCT05582590
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
Trial: NCT05865925
Drug: LY010616
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
Trial: NCT05554926
Drug: AEF0117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
Trial: NCT06058390
Drug: Bepirovirsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen will be administered.
Trial: NCT06319235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
Trial: NCT04975100
Drug: Placebo and SSRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
Trial: NCT06465992
Drug: Exparel 266 MG Per 20 ML Injection
RxNorm normalized name: Exparel 266 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block
Trial: NCT00111124
Drug: Enbrel®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04166110
Drug: Predetermined treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
Trial: NCT04166110
Drug: Variable treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment.
Trial: NCT05370898
Drug: Caltrate D
RxNorm normalized name: Caltrate Plus D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
Trial: NCT05370898
Drug: Chinese medicine prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
Trial: NCT05370898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
Trial: NCT04764201
Drug: HIP2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT04764201
Drug: HGP2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug
Trial: NCT05375435
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
Trial: NCT01692145
Drug: KCT-0809
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01692145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04827589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT06329674
Drug: AJU-A51
RxNorm normalized name: AJUGA REPTANS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT06329674
Drug: AJU-A51 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT06329674
Drug: A51R2 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT06385847
Drug: LY01005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 3.6 mg intramuscular LY01005
Trial: NCT05024422
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Pyridoxine (200 mg X 3 per day for a week)
Trial: NCT00002122
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05455372
Drug: PPI quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
Trial: NCT04731974
Drug: Melatonin 3 MG
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
Trial: NCT00000959
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04853498
Drug: TQB3720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an androgen receptor antagonists.
Trial: NCT04871347
Drug: TWP-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04774822
Drug: Mydriatics Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye dilating agent
Trial: NCT06364176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo through week 12
Trial: NCT05195892
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Trial: NCT04933799
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will match the study drug in dose, formulation, route and frequency.
Trial: NCT05176782
Drug: HTK cardioplegia
RxNorm normalized name: cardioplegia solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
Trial: NCT05176782
Drug: Cold Cadioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
Trial: NCT05072262
Drug: Nepafenac Ophthalmic
RxNorm normalized name: nepafenac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nepafenac (Nevanac) 3 mg/ml
Trial: NCT04666922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; 0.9% saline for injection
Trial: NCT05065190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00198302
Drug: Aurexis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05715736
Drug: APB-R3
RxNorm normalized name: APB 8 MG/ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
Trial: NCT05715736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.90% Normal Saline only
Trial: NCT05342519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
Trial: NCT04830878
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic and intraoperative intravitreal injection of methotrexate
Trial: NCT06280495
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
Trial: NCT06547385
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days